TheranosticTrials.org

Clinical Trial · NCT06809426

Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer

Overview

Evaluating the safety and antitumor efficacy of 177Lu-LNC1011

Sponsor

Affiliated Hospital of Jiangnan University

Phase

N/A

ClinicalTrials.gov

NCT06809426

Drug / Compound

LNC1011

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: DOTA

Eligibility

Inclusion

  • a physical status score of ≤2 according to Eastern Cooperative Oncology Group (ECOG) criteria.
  • PSMA positivity confirmed by 68Ga -PSMA PET/CT.
  • histologically or cytologically defined prostate cancer, the patients have not been treated or have exhausted all treatment.
  • meet the Prostate Cancer Working Group 3 (PCWG3) diagnosis of metastatic desmoplasia-resistant prostate cancer (mCRPC), including: a) the presence of a desmoplasia level of serum testosterone (serum testosterone \<50 ng/dL or 1.7 nmol/L); b) and the presence of one of the following: - serum PSA progression: PSA \>1 ng/mL and 2 consecutive rises in PSA 1 week apart, 2 greater than 50% of the nadir; or a bone scan suggestive of ≥2 new bone lesions; or CT or MRI suggestive of progression of soft tissue lesions (RECIST 1.1).

Exclusion

  • Patients who did not meet the requirements as assessed by the investigator.